Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.
Back
RX Review: Updates and Unmet Needs in HFmrEF/HFpEF—The Role of Finerenone
A trio of advanced heart failure specialists discusses how the approval of finerenone and other recent updates impact management for heart failure with mildly reduced or preserved ejection fraction.
RX Review: Updates and Unmet Needs in HFmrEF/HFpEF—The Role of Finerenone
Episodes
All
All
Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.
Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.
Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
3
The HCPFive: Top News for Healthcare Providers from the Week of 08/16
4
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
5